![Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study](https://www.tandfonline.com/cms/asset/566718b8-3b24-46b6-83c0-84be41740313/didr_a_331647_f0002_c.jpg)
Full article: Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
![JCM | Free Full-Text | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV JCM | Free Full-Text | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV](https://www.mdpi.com/jcm/jcm-12-07759/article_deploy/html/images/jcm-12-07759-g001.png)
JCM | Free Full-Text | Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
![Diagram comparing initial use BIC/TAF/FTC with switching to BIC/TAF/FTC... | Download Scientific Diagram Diagram comparing initial use BIC/TAF/FTC with switching to BIC/TAF/FTC... | Download Scientific Diagram](https://www.researchgate.net/publication/377497387/figure/fig1/AS:11431281224943894@1708497702280/Diagram-comparing-initial-use-BIC-TAF-FTC-with-switchingto-BIC-TAF-FTC-among-PLWH.jpg)
Diagram comparing initial use BIC/TAF/FTC with switching to BIC/TAF/FTC... | Download Scientific Diagram
![Randomized clinical trials of BIC/FTC/TAF and DTG/3TC in naïve patients. | Download Scientific Diagram Randomized clinical trials of BIC/FTC/TAF and DTG/3TC in naïve patients. | Download Scientific Diagram](https://www.researchgate.net/profile/Carlos-Rubio-Terres/publication/365596187/figure/tbl1/AS:11431281103295754@1669649228223/Preferred-starting-ART-combinations-recommended-by-GeSIDA-7_Q320.jpg)
Randomized clinical trials of BIC/FTC/TAF and DTG/3TC in naïve patients. | Download Scientific Diagram
![INSIGHT: Wk 24 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis Receiving Rifampicin | CCO INSIGHT: Wk 24 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis Receiving Rifampicin | CCO](https://d8tzmbmuvomgp.cloudfront.net/medialibrary/00011/FDFA81C8-3513-4D6D-A6F1-9CBF5D28F52B.png)
INSIGHT: Wk 24 Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis Receiving Rifampicin | CCO
![Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/4ADBAD65-D2F2-4BF0-B988-AC12013CCCF6/OriginalThumbnail/THUMBNAIL_shutterstock_533717242.jpg)
Switching from EFV/FTC/TDF to BIC/FTC/TAF maintains virologic suppression in people living with HIV | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV | Infectious Diseases and Therapy Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV | Infectious Diseases and Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40121-021-00449-z/MediaObjects/40121_2021_449_Fig2_HTML.png)
Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV | Infectious Diseases and Therapy
![Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study](https://www.natap.org/2021/images/110521/110321-5/1106215.gif)
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
![Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study](https://www.natap.org/2021/images/110521/110321-5/1106216.gif)
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study
![Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study](https://www.natap.org/2021/images/110521/110321-5/1106211.gif)